222 related articles for article (PubMed ID: 22285864)
21. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
[TBL] [Abstract][Full Text] [Related]
22. Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
Aller S; Popescu A; Rao S; Morgan E; Gosiengfiao Y
Pediatr Blood Cancer; 2012 Jan; 58(1):98-100. PubMed ID: 21721105
[TBL] [Abstract][Full Text] [Related]
23. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
24. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Bianchi G; Loibl S; Zamagni C; Salvagni S; Raab G; Siena S; Laferriere N; Peña C; Lathia C; Bergamini L; Gianni L
Anticancer Drugs; 2009 Aug; 20(7):616-24. PubMed ID: 19739318
[TBL] [Abstract][Full Text] [Related]
25. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
26. [Standards, options and recommendations for blood tumor markers in thyroid cancers].
Pichon MF; Basuyau JP; Gory-Delabaere G; Eche N; Daver A; Blanc-Vincent MP; Riedinger JM; Deneux L; Bidart JM
Bull Cancer; 2001 Aug; 88(8):775-92. PubMed ID: 11578946
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib in metastatic thyroid cancer: a systematic review.
Thomas L; Lai SY; Dong W; Feng L; Dadu R; Regone RM; Cabanillas ME
Oncologist; 2014 Mar; 19(3):251-8. PubMed ID: 24563075
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Spector E; Franklin MJ; Truskinovsky AM; Dudek AZ
Acta Oncol; 2010; 49(1):104-6. PubMed ID: 19711206
[No Abstract] [Full Text] [Related]
29. Sorafenib: rays of hope in thyroid cancer.
Duntas LH; Bernardini R
Thyroid; 2010 Dec; 20(12):1351-8. PubMed ID: 20954817
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
31. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Chen L; Shen Y; Luo Q; Yu Y; Lu H; Zhu R
Thyroid; 2011 Feb; 21(2):119-24. PubMed ID: 21186953
[TBL] [Abstract][Full Text] [Related]
32. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience.
Deutschbein T; Matuszczyk A; Moeller LC; Unger N; Yuece A; Lahner H; Mann K; Petersenn S
Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):540-3. PubMed ID: 21667440
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
34. Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study.
Kim M; Kim TH; Shin DY; Lim DJ; Kim EY; Kim WB; Chung JH; Shong YK; Kim BH; Kim WG;
Thyroid; 2018 Mar; 28(3):340-348. PubMed ID: 29350109
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma.
Baudin E; Droz JP; Paz-Ares L; van Oosterom AT; Cullell-Young M; Schlumberger M
Am J Clin Oncol; 2010 Feb; 33(1):83-8. PubMed ID: 19704366
[TBL] [Abstract][Full Text] [Related]
36. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
37. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.
Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K
Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689
[TBL] [Abstract][Full Text] [Related]
38. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Woyach JA; Kloos RT; Ringel MD; Arbogast D; Collamore M; Zwiebel JA; Grever M; Villalona-Calero M; Shah MH
J Clin Endocrinol Metab; 2009 Jan; 94(1):164-70. PubMed ID: 18854394
[TBL] [Abstract][Full Text] [Related]
39. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
Kasibhatla M; Steinberg P; Meyer J; Ernstoff MS; George DJ
Clin Genitourin Cancer; 2007 Mar; 5(4):291-4. PubMed ID: 17553211
[TBL] [Abstract][Full Text] [Related]
40. Medullary thyroid carcinoma with nodular goiter carries an excellent prognosis.
Xu L; Wang WB; Zhao YP; Zhang TP; Liao Q; Chen G; Zhou L; Shu H
J Surg Oncol; 2012 Aug; 106(2):169-73. PubMed ID: 22354558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
